Targeted cancer drugs finally living up to the hype

Targeted cancer drugs finally living up to the hype
Big pharmaceutical companies are backing so-called antibody-drug conjugates. (Image: Bloomberg)
Bloomberg
By Lisa JarvisCancer drugs that work like heat-seeking missiles to deliver chemicals directly to tumours are having a bit of a moment. Pharmaceutical companies, in need of assets to counter flagging sales, are making these so-called antibody-drug conjugates the technology of choice in oncology dealmaking, as illustrated by the recent US$10.1 billion (NZ$16.5b) acquisition of ImmunoGen by AbbVie.If that trend sounds vaguely familiar, you have probably been following the pharma industry for too long. The field has gone through waves of hype and i...

More Bloomberg

Firm wants to make purchasing cannabis super easy
Retail

Firm wants to make purchasing cannabis super easy

Verano invites shoppers to grab a basket and get their pot direct off the shelf.

Bloomberg 29 Jun 2025
Iran-Israel conflict spreads to hacks on banks, crypto
Bloomberg

Iran-Israel conflict spreads to hacks on banks, crypto

Pro-Israel hackers announced a new breach targeting an Iranian crypto exchange.

Bloomberg 19 Jun 2025
Here are the 10 best hotels in the world
The Life

Here are the 10 best hotels in the world

Its top 10 list consists entirely of tied scores for the top prize.

Bloomberg 15 Jun 2025
Afghan refugees should be treated same as South Africans
Bloomberg Opinion

Afghan refugees should be treated same as South Africans

The greater outrage is the suspension of a refugee programme that is so badly needed.

Bloomberg 17 May 2025